Stay updated on Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial

Sign up to get notified when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The clinical trial record is displayed in place of a 403 error page, showing study details, outcomes, eligibility information, locations, and supporting documents.
    Difference
    90%
    Check dated 2026-11-08T15:19:31.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T16:29:18.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition in terminology, stating that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the change.
    Difference
    1%
    Check dated 2026-10-25T17:21:24.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:38:58.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The site revision displayed in the footer changed from v3.7.0 to v3.7.1 on the forbidden page.
    Difference
    0.2%
    Check dated 2026-10-11T22:40:32.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the expected study content and blocking access to the NCT03318939 record. This appears to be an access/configuration issue rather than a content update.
    Difference
    19%
    Check dated 2026-09-20T19:53:33.000Z thumbnail image

Stay in the know with updates to Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.